Substitution of citrate with tissue plasminogen activator (rt-PA) for catheter lock does not improve patency of tunnelled haemodialysis catheters in a randomised trial
| Autor: | Richtrova, Pavlina, Mares, Jan, Kielberger, Lukas, Klaboch, Jan, Eiselt, Jaromir, Reischig, Tomas |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Aged
80 and over Male Drug Substitution Middle Aged lcsh:Diseases of the genitourinary system. Urology lcsh:RC870-923 Double-Blind Method Fibrinolytic Agents Renal Dialysis Tissue Plasminogen Activator Central Venous Catheters Humans Female Citrates Prospective Studies Vascular Patency Research Article Aged |
| Zdroj: | BMC Nephrology BMC Nephrology, Vol 22, Iss 1, Pp 1-7 (2021) |
| ISSN: | 1471-2369 |
| Popis: | Backround The study aim was to establish if substitution of citrate with rt-PA for catheter lock once weekly can reduce the incidence of catheter-related blood stream infections (CR-BSI) or improve patency of tunneled haemodialysis catheters. Methods All incident patients undergoing insertion of a tunneled haemodialysis catheter were screened and included except those suffering infection or using oral anticoagulation. Study participants were randomized into two arms according to the solution applied as catheter lock: receiving either trisodium citrate (Citra-LockTM 4%) only or rt-PA (Actilyse® 1 mg/ml) on the middle session each week with citrate used on the first and third sessions. The incidence of CR-BSI (confirmed by positive blood culture), catheter non-function (complete obstruction), and malfunction (blood flow |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink